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Abstract
Liposomes are widely used for systemic delivery of chemotherapeutic agents to reduce their 
nonspecific side effects. Gemcitabine (Gem) makes a great candidate for liposomal encapsulation 
due to the short half-life and non-specific side effects; however, it has been difficult to achieve 
liposomal Gem with high drug loading capacity. Remote loading, which uses a transmembrane pH 
gradient to induce influx of drug and locks the drug in the core as a sulfate complex, does not 
serve Gem as efficiently as doxorubicin (Dox) due to the low pKa value of Gem. Existing studies 
have attempted to improve Gem loading capacity in liposomes by employing lipophilic Gem 
derivatives or creating a high concentration gradient for active loading into the hydrophilic cores 
(small volume loading). In this study we combine remote loading approach and small volume 
loading or hypertonic loading, a new approach to induce the influx of Gem into the preformed 
liposomes by high osmotic pressure, to achieve a Gem loading capacity of 9.4 – 10.3 wt% in 
contrast to 0.14 – 3.8 wt% of the conventional methods. Liposomal Gem showed a good stability 
during storage, sustained-release over 120 h in vitro, enhanced cellular uptake and improved 
cytotoxicity as compared to free Gem. Liposomal Gem showed a synergistic effect with liposomal 
Dox on Huh7 hepatocellular carcinoma cells. A mixture of liposomal Gem and liposomal Dox 
delivered both drugs to the tumor more efficiently than a free drug mixture and showed a relatively 
good anti-tumor effect in a xenograft model of hepatocellular carcinoma. This study shows that 
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bioactive liposomal Gem with high drug loading capacity can be produced by remote loading 
combined with additional approaches to increase drug influx into the liposomes.
Keywords
Liposomes; drug loading capacity; gemcitabine; small volume loading; hypertonic loading; remote 
loading
1. Introduction
Liposomal drug carriers are used to reduce non-specific side effects of systemic 
chemotherapy. An important feature of liposomes is the versatility: liposomes can carry both 
hydrophilic and lipophilic drugs, with the former in the aqueous core compartment and the 
latter in the lipid bilayer membrane, respectively. Hydrophilic drugs can be passively loaded 
in the aqueous core during the hydration of the lipid film as part of the hydrating medium. 
Alternatively, weak acid or base drugs can be brought into the core compartment of 
preformed liposomes via chemical gradients across the lipid bilayer.1, 2 In case of base 
drugs, liposomes are filled with ammonium salts of sulfate, citrate, phosphate, or acetate, 
which ionize to ammonium and the counterions.3 The ammonium further dissociates to 
ammonia and proton, where the former with relatively high transmembrane diffusivity 
moves out of the liposomes leaving behind protons with lower diffusivity.1 The differential 
transmembrane diffusivity results in the acidification of the liposome interior, inducing 
ionization of the drug and its complexation with counterions, which forms a membrane-
impermeable ionic drug complex. A high concentration gradient of free drug, thereby 
formed, induces the influx of a drug into the liposomes (Supporting Fig. 1a). This method, 
called ‘remote loading’, has been employed in liposomal formulations of doxorubicin (Dox),
4
 bringing significant improvement in pharmacokinetics and safety profiles of the drug in 
humans.4–6
While the remote loading method can encapsulate drugs with a higher loading capacity 
(drug to liposome weight ratio) than the passive loading, it does not work for all the weak 
acid or base drugs. Gemcitabine (Gem), a prodrug of 2’,2’-difluorodeoxycytidine 5’-
triphosphate (dFdCTP) serving as a competitive inhibitor of dCTP in DNA polymerization,7 
is an exemplary drug that is difficult to encapsulate in liposomes. As a weak base, Gem can 
form an ionic complex with sulfate but not encapsulated in liposomes as efficiently as Dox 
by the remote loading method.8 Gem with a pKa value of pH 3.6 does not ionize in the 
acidic aqueous compartment of liposomes as extensively as Dox (pKa: pH 8.68); thus, the 
pH gradient across the membrane does not translate to a high concentration gradient of 
unionized Gem.8 Therefore, the maximum loading capacity of Gem that can be achieved by 
the remote loading is no higher than 1 wt%.8, 9 The low drug loading capacity is problematic 
for several reasons. First of all, a large loss of drug during the preparation is not economical.
4
 Secondly, inefficient drug loading necessitates the use of a large amount of polar lipids that 
may cause unintended biological effects.10 Moreover, the increased total dose due to the low 
drug loading increases the injection volume and/or the concentration of liposomes to the 
extent that they become the dose-limiting factors.11, 12 A large dose of liposomes has also 
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met with an increased toxicity in mice, due to the delayed tissue distribution of liposomes 
accompanied by the extended circulation, which increases the chances of free drug leakage.
13
Consistent with the difficulty in efficient loading, no viable liposomal Gem product is 
currently available on the market. Nevertheless, there are several compelling reasons to 
develop liposomal Gem. Upon systemic administration, Gem undergoes rapid metabolism 
and renal clearance with a half-life of 8–17 min.14 Non-specific distribution of Gem induces 
serious side effects such as myelosuppression, neutropenia, thrombocytopenia, and anemia.
15
 Liposomal Gem has the potential to improve the bioavailability and safety of Gem. 
Moreover, Gem is broadly pursued as a combination therapy with Dox in the treatment of 
breast cancer16, 17 and hepatocellular carcinoma18, 19 for a synergistic effect.20–25 
Liposomal Gem will be a more effective counterpart of liposomal Dox in achieving co-
localization of the drug combination. Therefore, there is a strong unmet need for efficient 
liposomal encapsulation of Gem.
An approach to improve liposomal encapsulation of Gem involves the incubation of 
preformed liposomes in a small volume of concentrated Gem solution, which keeps the 
external Gem at the saturation solubility and thus generates the maximum concentration 
gradient across the liposomal membrane.8 With the small volume loading method, the 
loading capacity of Gem in the liposomes increased from 0.2 wt% to 4 wt%.8 Another 
approach uses lipophilic Gem prodrugs, such as valeroyl, heptanoyl, lauroyl and stearoyl 
linear acyl derivatives of Gem, for liposomal encapsulation, achieving a loading capacity of 
up to 24 mol% (8.6 wt% as Gem).26
In this study, we explore various strategies to further increase Gem loading in liposomes, 
including a new method, called hypertonic loading. This simple method utilizes high 
osmotic pressure across the lipid bilayer, which induces the influx of external water phase 
containing unionized Gem. The hypertonic loading and small volume loading methods are 
combined with remote loading to reduce the back diffusion of Gem from liposomes. The 
optimized liposomal Gem is characterized with respect to the physicochemical properties 
and in vitro activities, as compared with liposomal Dox. The in vivo efficacy of liposomal 
Gem is tested in the context of combination therapy with liposomal Dox in a xenograft 
model of Huh7 hepatocellular carcinoma.
2. Materials and Methods
2.1. Materials
Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), cholesterol and N-(carbonyl-
methoxypolyethylene-glycol-2000)-1, 2-distearoyl-sn-glycero-3-phospho-ethanolamine 
(DSPE-PEG2000) were purchased from Avanti Polar Lipids (Alabaster, AL). Gemcitabine 
(Gem) and Doxorubicin HCl (Dox) were purchased from LC laboratories (Woburn, MA). 
Gemcitabine-5’-triphosphate (2’,2’-difluorodeoxycytidine 5’-triphosphate, dFdCTP) was 
purchased from Sierra Bioresearch (Tucson, AZ). 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was purchased from Invitrogen (Carlsbad, CA). 
Terminal deoxynucleotidyl transferase dUTP nick end labeling kit (DeadEnd Fluorometric 
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TUNEL System) was purchased from Promega (Madison, WI). All other materials, 
including solvents, were purchased from Sigma Aldrich (St. Louis, MO).
2.2. Liposome preparation
Liposomes were prepared in the following procedure with variations in hydration and drug 
loading methods (Fig. 1). A mixture of DPPC, cholesterol, DSPE-PEG2000 at a weight ratio 
of 6:3:1 (20 mg in total) was dissolved in 3 mL of a 3:1 mixture of chloroform and 
methanol. For the preparation of fluorescently-labeled liposomes, 1 mg of cholesterol was 
replaced with 25-NBD cholesterol. A thin lipid film was obtained by removing the solvents 
with a rotary evaporator at 45 °C and hydrated according to the procedures detailed below. 
The hydrated lipid film was sonicated in a sonic water bath (Bransonic ultrasonic Co, 
Danbury, CT) for 15 min and extruded through polycarbonate membranes with a pore size of 
400 nm and 200 nm, sequentially, using a Mini-extruder (Avanti polar lipid, Inc., AL). The 
drug-loaded liposomes were washed with deionized (DI) water 3 times by 
ultracentrifugation at 135,700 rcf at 4 °C and used as is unless specified otherwise. No drug 
was detectable in the supernatant collected after the 3rd centrifugation, which confirmed the 
complete removal of unencapsulated drug. In all methods, each batch used 20 mg of lipid 
components and 5 mg of Gem and/or 5 mg of Dox (theoretical loading capacity of 20 wt%).
Passive loading: The lipid film was hydrated with 1 mL of 5 mg/mL Gem solution and 
stirred in a rotary evaporator for 45 min at 45 °C, extruded and washed as described above. 
The Gem-loaded liposomes prepared by this method are called LPG.
Remote loading: The lipid film was hydrated 1.2 mL of 250 mM ammonium sulfate 
solution and stirred in a rotary evaporator for 60 min at 45°C. The hydrated film was bath 
sonicated, extruded and collected by centrifugation at 305,400 rcf. The liposomal pellet was 
dispersed in 0.5 mL of 10 mg/mL Gem or Dox solution by bath sonication and incubated at 
60 °C overnight. The liposomes were then washed as described above. The Gem- or Dox-
loaded liposomes prepared by remote loading are called LRG and LRD.
Small volume loading27: The lipid film was hydrated in 1.2 mL of phosphate-buffered 
saline (PBS, pH 7.4). The hydrated film was bath sonicated for 10 min, extruded and 
collected by centrifugation at 305,400 rcf. The liposomal pellet was mixed with 0.1 mL of 
DI water containing 5 mg of Gem by 15 min bath sonication, followed by overnight 
incubation at 60 °C. The liposomes were then washed as described above. The Gem-loaded 
liposomes prepared by small volume loading are called LSG.
Hypertonic loading: The lipid film was hydrated in 1.2 mL of 462 mM sodium chloride 
solution. The hydrated film was bath sonicated, extruded and collected by centrifugation at 
305,400 rcf. The liposomal pellet was incubated in 0.5 mL of DI water containing 5 mg of 
Gem at 60 °C overnight. The liposomes were then washed as described above. The Gem-
loaded liposomes prepared by hypertonic loading are called LHG.
Combination of Remote loading and Small volume loading: The liposomal pellet 
prepared by the remote loading method was mixed with 0.1 mL of DI water containing 5 mg 
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of Gem by 15 min bath sonication, followed by overnight incubation at 60 °C. The 
liposomes were then washed as described above. The Gem-loaded liposomes prepared by 
the combination of remote loading and small volume loading are called LRSG. Gem/Dox-
coloaded liposomes (LRSGD) were prepared by incubating the pellet in 0.1 mL of DI water 
containing 5 mg Gem and 5 mg Dox at 60 °C overnight.
Combination of Remote loading and Hypertonic loading: The lipid film was 
hydrated in 1.2 mL of DI water containing 250 mM Ammonium sulfate and 462 mM of 
sodium chloride. The liposomal pellet was incubated in 0.5 mL DI water containing 5 mg of 
Gem at 60 °C overnight. The liposomes were then washed as described above. The Gem-
loaded liposomes prepared by the combination of remote loading and hypertonic loading are 
called LRHG.
2.3. Liposome characterization
The z-average and zeta potential of each liposomal formulation were measured by a Malvern 
Zetasizer Nano ZS90 (Worcestershire, UK), as dispersed in DI water (z-average) or in 1 mM 
phosphate buffer (pH 7.4) (zeta potential). The liposomes were observed by the Tecnai F20 
transmission electron microscope (FEI, Hillsboro, OR) after negative staining with 1% 
uranyl acetate (Gem-loaded liposomes) or 1% phosphotungstic acid (Dox- or co-loaded 
liposomes). The size of particles in each micrograph was estimated by NIH ImageJ software 
(Bethesda, MD).
2.4. Drug loading capacity
The purified liposomes were lyophilized, accurately weighed, dispersed in 1 mL of 
acetonitrile and bath-sonicated in cold water for 2 h. The suspension was diluted with an 
equal volume of DI water and centrifuged at 16100 rcf for 20 min to obtain a clear 
supernatant. The supernatant was filtered through a 0.45 μm syringe filter and analyzed by 
high-pressure liquid chromatography (HPLC). HPLC analysis was performed by the Agilent 
1100 system (Agilent Technologies, Palo Alto, CA), equipped with a C18 column (25 cm × 
4.6 mm, particle size 5 μm) (Supelco, St. Louis, MO). Dox was eluted with a 70:30 mixture 
of water and acetonitrile with 0.1% trifluoroacetic acid at a flow rate of 0.8 mL/min and 
detected at 369 nm.28 Gem was eluted with a 90:10 mixture of water and acetonitrile at a 
flow rate of 1 mL/min and detected at 269 nm.29 The drug loading capacity (%) is defined as 
WD/WL × 100, where WD is the amount of drug detected and WL the total amount of drug-
loaded liposomes analyzed.
2.5. In vitro release kinetics of drug-loaded liposomes
Liposomes equivalent to 115 μg/mL of Gem or 250 μg/mL of Dox were placed in a Float-A-
Lyzer G2 dialysis device (Spectrum Laboratories, Inc., Rancho Dominguez, CA) with a 
molecular weight cut-off of 100 kDa. The device was incubated in 20 mL of PBS (pH 7.4 or 
pH 5.5) at 37 °C with constant agitation. At predetermined time points, 0.3 mL of the release 
medium was sampled and replaced with 0.3 mL of fresh buffer. The sampled buffer was 
filtered with a syringe filter (0.45 μm pore size) and analyzed by HPLC.
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2.6. Cytotoxicity of drug-loaded liposomes
Huh7 human hepatocellular carcinoma cells (donation of Prof. Wanqing Liu) were cultured 
in RPMI-1640 medium complemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL 
streptomycin at 37 °C in a humidified 5% CO2 atmosphere. Huh7 cells were seeded in a 96 
well plate at a density of 10,000 cells per well and grown to 70% confluence. Huh7 cells 
were exposed to free drug or liposomal preparations for 3 or 6 h. The cells were rinsed twice 
with fresh medium and kept in drug-free medium for 72 h. In another experiment, Huh7 
cells were incubated with a free Gem, LRSG, LRHG, free Dox, LRD, blank liposomes, free 
drug mixture, or liposome mixture for 72 h. The medium was then removed, and 15 μL of 5 
mg/mL MTT solution and 100 μL media were added to each well and incubated for 4 h at 
37 °C. Each well was then treated with 100 μL of stop/solubilization solution and agitated at 
37 °C overnight. The absorbance of dissolved formazan was measured at 562 nm by a 
SpectraMax M3 microplate reader (Molecular Devices, Sunnyvale, CA).
2.7. Determination of optimal sequence of combination treatments
For determination of the optimal sequence of drug treatments, the cells were incubated with 
free Gem on the first day and free Dox on the second day (or vice versa), with the third day 
in drug-free medium (Gem → Dox or Dox → Gem). Alternatively, the cells were incubated 
with a Gem/Dox on the first day followed by 2 d incubation in drug-free medium (Gem + 
Dox). MTT assay was performed after the three days. The half maximal inhibitory 
concentration (IC50) of each treatment was determined by GraphPad prism 7 (San Diego, 
CA). The combination index (CI) of each treatment was determined by Compusyn 
(Combosyn, Inc., Paramus, NJ). The values of CI < 1, CI = 1, and CI > 1 represent synergy, 
additivity, and antagonism, respectively.30
2.8. Cellular uptake of drug-loaded liposomes
2.8.1. Quantitative analysis—Huh7 Cells were seeded in a 12 well plate at a density 
of 105 cells per well. After overnight incubation, the cells were treated with LRHG, LRSG, or 
free Gem at a concentration equivalent to 50 μM Gem, or with LRD or free Dox at a 
concentration equivalent to 50 μM Dox. At 3, 6, 12, and 24 h post-treatment, the cells were 
rinsed twice with cold PBS, trypsinized and collected by centrifugation at 233 rcf. The cell 
pellets were suspended in PBS and lysed by three cycles of freezing and thawing followed 
by probe sonication. The protein content in each cell lysate was measured by micro BCA 
assay. A hundred microliters of cell lysate was mixed with 200 μL of acetonitrile, bath 
sonicated for 1 h, and centrifuged at 16100 rcf for 30 min to separate a supernatant. The 
supernatant was evaporated under vacuum overnight and reconstituted in 100 μL of PBS. 
Dox was detected by the microplate reader at λEx/λEm of 488 nm/580 nm. dFdCTP was 
detected by HPLC using a 64:36 v/v mixture of two aqueous mobile phases: (i) KH2PO4 10 
mM, tetra butyl ammonium bromide (TBABr) 10 mM, pH 7 and 0.25% methanol and (ii) 
KH2PO4 250 mM, TBABr 10 mM, pH 7 and 15% methanol, run at 1.2 mL/min, and a 
detection wavelength of 271 nm.31
2.8.2. Confocal microscopic imaging—Huh7 cells were seeded in a 35 mm glass-
bottomed dish (Mat Tek Corp., Ashland, MA) at a density of 100,000 cells per dish. At 70% 
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confluence, the cells were treated with free Dox for 10 min or fluorescently labeled 
liposomes (*LRD, labeled with 25-NBD cholesterol) for 10 min, 3 h or 10 h. At each time 
point, the cells were rinsed twice with PBS. After nuclei staining with Hoechst 33342 (5 
μg/mL) for 10 min, the cells were rinsed again with PBS and imaged in medium by a Nikon-
A1R confocal microscope (Nikon America Inc., Melville, NY). For selected treatments, 
chloroquine was added 12 h prior to the treatment. The cells were rinsed with PBS and 
incubated with the labeled liposomes for confocal imaging.
2.8.3. Flow cytometry—To supplement the confocal microscopic imaging, flow 
cytometry was performed with cells treated in the same manner as above. Huh7 cells were 
seeded in a 48 well-plate at a density of 50,000 per well. After overnight incubation, the 
cells were treated with free Dox for 10 min or LRD for 10 min, 3h or 10 h at a concentration 
equivalent to 50 μM Dox. Cells were then rinsed with PBS and analyzed by an Accuri C6 
flow cytometer (BD Biosciences, San Jose, CA) with an FL-2 detector (λex/λem = 488 
nm/585 nm).
2.9. In vivo delivery of liposomal combination
2.9.1. Huh7 xenograft model—All the animal procedures were approved by Purdue 
Animal Care and Use Committee, in conformity with the NIH guideline for the care and use 
of laboratory animals. 4–5 week old male athymic nude mice (Foxn1nu) were purchased 
from Envigo (Indianapolis, IN) and acclimatized for 4 days prior to the procedure. Each 
mouse received a subcutaneous injection of 107 Huh7 cells in the upper flank of the right 
hind leg. The tumor length (L) and width (W) were measured by a digital caliber, and tumor 
volume (V) was calculated according to the equation: V = (L × W2)/2.
2.9.2. Intravenous administration of treatments in Huh7 tumor bearing mice
—When the tumor reached 100 mm3 (~21 days after inoculation), the mice were 
randomized into 3 groups and treated with a free drug mixture comprising 1.8 mg/kg/dose 
Gem and 4 mg/kg/dose of Dox (n = 4) or a mixture of their liposomal counterparts at the 
same doses (n = 4) by tail-vein injection. Eight hours post injection, the mice were sacrificed 
to sample blood and tumors. Blood was collected in BD Vacutainer containing lithium 
heparin (BD Biosciences, San Jose, CA) and centrifuged at 4000 rcf to separate plasma.
2.9.3. Sample preparation—For the plasma sample extraction, 20 μL of the sample or 
calibration standard was transferred to glass tubes, followed by the addition of an internal 
standard and ethyl acetate. The samples were then vortexed, centrifuged, and the organic 
layer was transferred to a clean glass tube, and evaporated to dryness. The samples were 
then reconstituted with mobile phase for HPLC-MS/MS analysis. The tumor sample was 
weighed and transferred to a glass tube. PBS was added to the sample to bring the total 
volume to 1 mL. The tissue was then homogenized using a TissueRuptor® with a single use 
disposable probe. An 0.5 mL aliquot was transferred to a clean glass tube and handled in the 
same manner as plasma.
2.9.4. Drug analysis—Dox, doxorubicinol (a metabolite of Dox), Gem, and 2’,2’-
difluorodeoxyuridine (dFdU, a deaminated metabolite of Gem) in each sample were 
Hassan et al. Page 7
Mol Pharm. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
analyzed by HPLC-MS/MS (Agilent 1290 pump, Eskigent Autosampler, and 5500 
QTRAP® Sciex). Temazepam (20 μL of 0.1 ng/μL) was used as an internal standard for Dox 
and doxorubicinol, and 5-azacytadine (20 μL of 1 ng/μL) for Gem and dFdU. Dox, 
doxorubicinol, and temazepam were separated on a Phenomenex Monolithic Onyx C18 100 
× 4.6 mm column with acetonitrile containing 0.1% formic acid delivered on a gradient at a 
flow rate of 800 μL/min. Gem, dFdU, and 5-azacytadine were separated on an Agilent 
Zorbax C8 250 × 4.6 mm 5-micron column with acetonitrile containing 5 mM ammonium 
formate delivered on a gradient at a flow rate of 800 μL/min. The mass spectrometer utilized 
an electrospray ionization probe run in positive mode. The multiple reaction monitoring 
(MRM) Q1/Q3 (m/z) transitions for Dox, doxorubicinol, and temazepam were 544.0/369.9, 
546.3/398.9, and 301.0/255.2, respectively. The MRM Q1/Q3 (m/z) transitions for Gem, 
dFdU, and 5-azacytadine were 264.0/112.1, 265.0/112.8, and 245.0/113.0, respectively. The 
lower limit of quantification (LOQ) was 3 ng/mL for both Dox and doxorubicinol and 1 
ng/mL for both Gem and dFdU.
2.10. Anti-tumor efficacy of liposomal combination
Tumor-bearing mice were prepared in the same way as in 2.9.1. When the tumor volume 
reached 100 mm3, the mice were randomized to 3 groups and treated with PBS (n = 6), a 
free drug mixture comprising 1.8 mg/kg/dose Gem and 4 mg/kg/dose of Dox (n = 8), or a 
mixture of their liposomal counterparts at the same doses (n = 8) by tail-vein injection. Each 
treatment was repeated four times with a 7-day interval (q7d × 4). The tumor volume and 
body weight were monitored daily. The tumor specific growth rate was calculated as ΔlogV/
Δt (t: time in days).32 Animals with tumors reaching more than 10% of the body weight 
were humanely euthanized.
To examine the effect of each treatment on tumor and major organs, another set of tumor-
bearing mice were treated once with PBS (n = 2), a free drug mixture (1.8 mg/kg Gem and 4 
mg/kg of Dox) (n = 3), or a mixture of their liposomal counterparts (n = 3) by tail-vein 
injection. One week after the treatment, animals were humanely sacrificed, and the organs 
and tumors were collected, fixed in 10% neutral buffered formalin solution, embedded in 
paraffin, and stained with hematoxylin and eosin for histological evaluation. Unstained 
paraffin-embedded tumor sections were analyzed by the TUNEL assay for the evaluation of 
pro-apoptotic effect of the treatment. Three to four randomly selected fields per each 
TUNEL-stained slide were imaged with a Nikon A1R confocal microscope and analyzed by 
Nikon A1R image analysis software to count apoptotic cells and nuclei. Percent apoptotic 
cells were calculated as the ratio of the number of apoptotic cells to the number of nuclei.
2.11. Statistical analysis
All data were expressed as means ± standard deviations. Statistical analyses were performed 
with GraphPad Prism 7 (San Diego, CA). Data were analyzed by ANOVA test followed by 
recommended post-hoc multiple comparisons tests. A p value of < 0.05 was considered 
statistically significant.
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3. Results and Discussion
3.1. Effect of preparation methods on liposomal drug loading
Gem-loaded liposomes by passive loading (LPG) showed a negligible drug loading of 0.14 
wt%. However, variations in the drug loading method, such as remote loading, small volume 
loading, and hypertonic loading, increased the Gem loading capacity to 3.7 wt% (LRG), 3.8 
wt% (LSG), and 2.4 wt% (LHG), respectively (Supporting Table 1). With the combination of 
remote loading and small volume or hypertonic loading (Table 1), the Gem loading capacity 
further increased to 9.4 ± 0.6 wt% (LRSG) and 10.3 ± 1.4 wt% (LRHG). Dox-loaded 
liposomes, made by the remote loading method (LRD), showed the loading capacity of 21.3 
± 2.5 wt%, which approaches the theoretical Dox content (5/(20 + 5) = 20 wt%), consistent 
with a previous report.33
The remote loading relies on the pH gradient across the lipid bilayer created by the 
ionization of ammonium sulfate and the diffusion of ammonia, which provides a driving 
force for the influx of unionized drug. The internalized drug undergoes ionization in the 
acidic internal pH (3.62) and forms a stable sulfate complex, which is precipitated inside the 
liposomes.1 This principle works well for Dox4 but not for Gem. Due to the low pKa value 
(3.6), the extent of Gem ionization in the interior of liposomes (ionized/unionized = 1) is not 
as high as Dox with a pKa value of 8.68 (ionized/unionized = 120,000); therefore, the 
loading capacity of LRG (3.7 wt%) was much lower than that of LRD (21.3 wt%). Of note, 
our loading capacity of LRG (3.7 wt%) is substantially higher than that reported by Xu et al 
(0.2 wt%).8 This difference may be attributable to the fact that the Gem concentration in the 
exterior of the liposomes was kept 38 times higher than Xu’s (10 mg/mL vs. 0.26 mg/mL), 
which helped increase the concentration gradient of unionized Gem across the lipid bilayer. 
This is consistent with the principle of the small volume loading, which employs the 
maximum concentration gradient to facilitate drug influx into the liposomes.8 With the small 
volume loading method, the loading capacity of LSG was 3.8 wt%, comparable to the 
previous studies (4 wt%8; 4.3 wt%29). The hypertonic loading method also helped to 
enhance the loading capacity of Gem. In this method, liposomes were filled with hypertonic 
sodium chloride solution (462 mM) and suspended in Gem solution (10 mg/mL: i.e., 38 
mM). The difference in ionic strengths created a high osmotic pressure inside the liposomes, 
pulling Gem along with water into the aqueous core of the liposomes. The combination of 
remote loading and small volume loading or hypertonic loading further increased the Gem 
loading. This enhancement demonstrates that the benefit of remote loading can be 
maximized when combined with additional means to increase the influx of unionized Gem, 
be it through increasing the concentration gradient (via small volume loading) or the osmotic 
pressure gradient (via hypertonic loading).
The combination of remote loading and small volume loading was also used to co-
encapsulate Dox and Gem (LRSGD). The loading contents of Dox and Gem were 10.0 ± 2.1 
wt% and 4.2 ± 1.0 wt%, respectively, about half the maximum drug contents of the 
liposomes loaded with Dox or Gem individually (LRD; LRSG or LRHG) (Table 1). This 
reduction in drug loading capacity may be explained by the competition between Gem and 
Dox for available sulfate.
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3.2. Particle characterization
The z-averages of liposomes measured by DLS were 210–220 nm (Table 1). The zeta 
potential measured in 1 mM phosphate buffer (pH 7.4) was consistently negative irrespective 
of the loaded drug, likely due to the presence of cholesterol that reduces the binding of 
sodium ions to the membrane surface.34 DSPE-PEG2000 may also have contributed to the 
negative charge.35 The particle size and zeta potential of Gem-loaded liposomes (LRSG, 
LRHG) did not change significantly over 3-month storage at 4 °C (Table 2). LRD was also 
stable for the first 2 months but showed a slight increase in size in the third month. LRSGD 
showed significant size increase after 1-month storage. Despite variable size stability, the 
drug contents did not change during the storage indicating stable liposomal encapsulation of 
the drugs (Table 2).
The particle size of the Gem-loaded liposomes (LRSG, LRHG) estimated by TEM using 
ImageJ was consistent with the DLS measurement, which ranged from 152 to 315 nm (Fig. 
2). In TEM micrographs, the interior of LRSG and LRHG appeared darker than blank 
counterparts, with many of them showing a triangular shape, which is likely the Gem sulfate 
complex. LRD liposomes were filled with rod-shape precipitates (data not shown), typical of 
Dox sulfate complexes.36
3.3. In vitro release kinetics of liposomal drugs
The drug release from liposomes were examined in phosphate-buffered saline (phosphate 10 
mM) at pH 7.4 and pH 5.5, representing extracellular and lysosomal pHs, respectively (Fig. 
3). Both LRSG and LRHG showed a sustained Gem release, irrespective of the pH (except for 
the initial delay with LRSG at pH 7.4), with ~60% of the encapsulated Gem released by 120 
h. Given the contrast with LPG (passive loading with no sulfate complex), which released 
~100% of drug in 5 h, the sustained release profiles of LRSG and LRHG may be attributable 
to the formation of Gem sulfate complex, which does not readily pass the lipid bilayer.9, 14 
LRD also showed a sustained release profile with a similar mechanism, but the extent of Dox 
release was pH-dependent (40% at pH 7.4 and 60% at pH 5.5 by 120 h). The pH-dependent 
Dox release from liposomal Dox has been reported in the literature.3, 37 The increased Dox 
release at acidic medium is likely driven by the influx of protons, which causes the 
dissociation (dissolution) of Dox sulfate (Supporting Fig. 1b). The extent of pH-dependence 
in drug release is shown to vary with the type of counterions, which determines their 
tendency of protonation, hence the dissolution of ionic Dox complex.3 The acidic pH would 
not have affected Gem release as much as it did Dox, as a relatively large fraction of Gem 
would be present in the free base form due to the low pKa value.
LRSGD showed different drug release patterns (Supporting Fig. 2), indicating the influence 
of one drug on the other. Gem release from the LRSGD showed pH-dependence, with 71% 
released at pH 7.4 and 82% at pH 5.5 by 120 h. This suggests that Dox and Gem have shared 
sulfate to form a co-complex (i.e., Dox-sulfate-Gem) and the dissolution of Dox sulfate at 
acidic pH induced concomitant dissociation of Gem. Dox release from the LRSGD continued 
to be pH-dependent but was overall suppressed by 20%, likely due to the competition with 
Gem in the co-complex. LRSGD was excluded in the following studies, since it had no 
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outstanding advantages in drug loading capacity and storage stability but confounding 
interactions between the drugs in controlled release.
3.4. Cytotoxicity of liposomal drugs vs. free drug counterparts
LRSG, LRHG and LRD incubated with Huh7 cells for 72 h showed similar cytotoxicity as 
free drug counterparts (Fig. 4) with comparable IC50 values (1.6 μM, 4.3 μM, 3.0 μM for 
free Gem, LRSG, and LRHG; 0.25 μM and 0.32 μM for free Dox and LRD). Blank liposomes 
did not show significant cytotoxicity (Supporting Fig. 3). This result indicates that the 
liposomes released active drugs during the incubation.
In another setting, the cells were exposed to the liposomes for a short time period (6 h for 
Gem; 3 h for Dox) to simulate dynamic in vivo environment, where the contact between the 
treatment and tumor cells declines with time. The cell viability after short-term exposure 
treatment reflects the effect of drug (as the released drug or liposomal drug) taken up by the 
cells during the exposure. With 6 h incubation, LRSG and LRHG showed greater toxicity 
than the equivalent dose of free Gem, reaching a statistical difference at 100 μM (Fig. 5a). 
Given that Gem release from the liposomes in the first 6 h was <20%, the greater toxicity of 
liposomal Gem may mainly be attributable to the improvement in cellular uptake of the 
drug, which is necessary to its intracellular conversion to bioactive metabolite (dFdCTP).7 
Free Gem is known to enter cells poorly due to the high hydrophilicity38 and the dependence 
on nucleoside transporters.39–41 Liposomal Gem may be more efficient than free Gem as 
they can enter cells42 by diverse endocytic pathways.43 In contrast, LRD showed less 
toxicity than free Dox after 3 h exposure (significant difference shown at a concentration 
equivalent to Dox 1 μM, Fig. 5b), consistent with relatively slow Dox release. This suggests 
that liposomal Dox does not have advantage over free Dox as liposomal Gem does over free 
Gem in the cell level.
3.5. Cellular uptake of liposomal drugs vs. free drug counterparts
To verify whether liposomal Gem enters cells more efficiently than free Gem (and liposomal 
Dox does the opposite), cellular uptake of each liposomes was investigated by measuring 
intracellular drug contents after timed incubation. As expected, Huh7 cells incubated with 
LRSG or LRHG showed greater intracellular concentration of dFdCTP than those treated 
with free Gem (statistical difference shown at 6 and 12 h incubation, Fig. 5c). This result 
supports that the liposomal Gem improves the activity of Gem by increasing its intracellular 
delivery. LRD vs. free Dox showed the opposite trend, with free Dox entering cells more 
efficiently than LRD, as evident at 3, 6, and 12 h (Fig. 5d). The attenuated cellular uptake 
relative to free Dox coupled with slow drug release (Fig. 3b) may account for the relatively 
low activity of LRD after 3 h exposure (Fig. 5b).
Confocal microscope imaging further confirmed the delayed cellular uptake and drug release 
of LRD. Free Dox entered the cells more quickly than *LRD (LRD labeled with 25-NBD 
cholesterol), appearing in the nuclei as early as in 10 min (Fig. 6a). Flow cytometry 
confirmed that Dox fluorescence intensity of free Dox-treated cells was stronger than that of 
the LRD-treated cells after 10 min incubation (Supporting Fig. 4a). While the fluorescent 
cholesterol signal was observed in the cells in 10 min indicating the uptake of liposomes, 
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Dox signal took longer to show up in the cells. The time-dependent increase of Dox signal in 
LRD-treated cells was observed by flow cytometry (Supporting Fig. 4b). When Dox was 
detected in the LRD-treated cells (at 3 h and 10 h), part of the signal was present in the 
cytosol in addition to the nucleus, reflecting the fraction of Dox remaining in the liposomes 
(Fig. 6b). When the cells were pretreated with chloroquine (CQ), which prevents the 
acidification of the lysosomes by consuming protons,44–46 Dox fluorescence appeared as 
punctate signals in the cytosol with little signal in the nuclei. This indicates that *LRD was 
taken up by endocytosis and trafficked to lysosomes and Dox release was delayed in the CQ-
filled (hence less acidic) lysosomes, consistent with the acid-dependent release kinetics of 
liposomal Dox (Fig. 3b).
3.6. Optimization of Dox/Gem combination
The bioactivity of liposomal Gem was tested in the context of combination therapy with 
Dox. To determine the optimal regimen for Gem/Dox combination treatment, free drug 
combinations were first tested with Huh7 cells in different sequences and ratios, keeping the 
exposure to each drug to 1 day. Simultaneous treatment (Gem + Dox) yielded relatively low 
CI values compared to sequential treatments at all ratios (Fig. 7a, Table 3). Accordingly, 
Huh7 cells were treated with combinations of liposomes simultaneously (LRSG + LRD or 
LRHG + LRD). The liposomal mixtures were found to be synergistic at all tested ratios (Fig. 
7b, Table 4), when measured after 3 d exposure. For the following in vivo study, LRSG + 
LRD combination at 1:1 molar ratio was selected to avoid using one drug in a 
disproportionately high dose to exceed its maximum tolerated dose.
3.7. In vivo delivery of liposomal combination
Huh7 tumor bearing mice were administered intravenously with 1:1 molar combination of 
LRSG + LRD or free drug mixture to compare their in vivo delivery. Animals were sacrificed 
at 8 h post-treatment, and the concentrations of each drug and its metabolite in plasma and 
tumor measured (Supporting Figs. 5 and 6). The samples from animals treated with the 
liposomal combination (LRSG + LRD) showed significant levels of Gem and Dox in either 
the original or metabolite form (Fig. 8). In contrast, the drugs were undetectable in the 
samples of free drug mixture-treated group. This difference between liposomal and free drug 
mixtures is consistent with the extended circulation time of PEGylated liposomes.47–49 
Notably, most Gem in tumors of the liposomal combination group was detected in the 
metabolized form (dFdU). This indicates that LRSG arriving at tumors was taken up by the 
cells and underwent intracellular metabolism, in accordance with in vitro cellular uptake of 
liposomal Gem’s (Fig. 5c). Nevertheless, it is noted that this measurement was performed at 
a single time point (8 h) after the treatment. Pharmacokinetics and biodistribution studies 
remain to be performed in order to fully evaluate the contribution of the liposomal 
formulation to in vivo delivery of Gem.
3.8. Anti-tumor efficacy of liposomal combination
LRSG + LRD combination was simultaneously administered to male nude mice inoculated 
with subcutaneous Huh7 tumors at a q7d × 4 schedule and compared with those treated with 
free drug combination at the equivalent dose (Fig. 9a). The total administered dose (1.8 
mg/kg/dose Gem and 4 mg/kg/dose of Dox, q7d × 4) was below the reported maximum 
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tolerated dose of each drug (16 mg/kg for Gem50; 30 mg/kg for Dox51). Both free drug and 
liposomal combinations were well tolerated without causing >20% weight loss during the 
treatment (Supporting Fig. 7) and induced significant delay in tumor growth as compared to 
PBS (free drug combination: p < 0.01; liposomal combination: p < 0.001 vs. PBS group, by 
Tukey’s test) (Fig. 9b, c). The animals treated with the liposomal combination showed a 
significant extension in the median survival time compared with the PBS or free drug 
combination-treated animals (Fig. 9d; p < 0.0001 vs. PBS group; p < 0.001 vs. free drug 
combination group by Log-rank (Mantel-Cox) test). Although the drug levels in tumors (Fig. 
8) suggest that both LRSG and LRD have played roles in the enhanced anti-tumor efficacy, 
the relative contribution of each liposomal drug to the effect may not be ascertained without 
comparison with the monotherapy based on single liposome treatment.
The effects of each treatment on tumor and other major organs that may be affected by free 
drug (heart, liver or kidney)52,53 were examined at 7 days after single treatment, by TUNEL 
assay and histological evaluation. In TUNEL assay, the tumor sections of LRSG+LRD-
treated animals showed higher numbers of apoptotic cells than those of the PBS-treated 
animals, consistent with the specific tumor growth rate, whereas those treated with free drug 
combination showed no significant difference from the control group at this time point (Fig. 
10a; Supporting Fig. 8). Histological evaluation showed a consistent trend, indicating a 
greater population of dying cells in LRSG+LRD-treated tumors (Fig. 10b; Supporting Fig. 9). 
The PBS-treated animals showed highly vascular tumors, where tumor cells were arranged 
in sheets with cellular and nuclear pleomorphism with abnormal nuclear morphology. Fifty-
seven mitotic figures were identified in ten 40× fields. In the tumors of animals treated with 
free drug combination, cellular morphology was similar to that of the control. Occasional 
cells were necrotic with hypereosinophilic cytoplasm and karryorhexis. On the other hand, 
tumors of animals treated with LRSG+LRD were composed of neoplastic cells arranged in 
sheets and contained multifocal areas of cellular necrosis. Necrotic tumor cells had a 
hypereosinophilic cytoplasm with shrunken nuclei, and these cells were surrounded by 
erythrocytes and mixed inflammatory cell population. Differential toxicity on off-target 
organs between free drug combination- and LRSG+LRD-treated animals was suspected 
based on the literature supporting the benefit of liposomal drug54–59 but not observed at the 
dose (one time treatment of 1.8 mg/kg Gem and 4 mg/kg of Dox) and time point (7 days 
after treatment) used in this study, with neither group showing abnormality in those organs 
compared to the PBS-treated group.
4. Conclusion
Liposomal Gem with high drug loading capacity was produced by remote loading, small 
volume loading, hypertonic loading, and their combinations. Each method increased the 
loading capacity from 0.14 wt% to 3.7 wt% (remote loading), 3.8 wt% (small volume 
loading), and 2.7 wt% (hypertonic loading), respectively. The combination of remote loading 
and small volume loading or hypertonic loading further increased the Gem loading capacity 
to 9.4 ± 0.6 wt% and 10.3 ± 1.4 wt%, respectively, based on the increased influx and 
efficient entrapment of Gem in the liposomal core. The liposomal Gem showed high 
stability, sustained drug release, enhanced cellular uptake, and improved cytotoxicity as 
compared to free Gem. Liposomal Gem showed a synergistic effect with liposomal Dox on 
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Huh7 hepatocellular carcinoma cells. A mixture of liposomal Gem and liposomal Dox 
delivered both drugs to the tumor more efficiently than a free drug mixture and showed a 
relatively good anti-tumor effect in a xenograft model of Huh7 tumor. This study 
demonstrates the feasibility of producing bioactive liposomal Gem with an unprecedented 
high drug loading capacity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. 
Schematic description of the liposome preparation. (a) Overview of passive loading, remote 
loading, small volume loading, and hypertonic loading. (b-d) Envisioned mechanism of each 
method. d-N represents weak base drug such as Gem or Dox.
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Fig. 2. 
TEM images of LRSG, LRHG, blank LRH, and blank LRS. Scale bar: 200 nm.
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Fig. 3. 
In vitro release kinetics of (a) LRSG, LRHG and (b) LRD at pH 5.5 and 7.4. n = 3 
independent and identical batches. Mean ± standard deviation (s.d.).
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Fig. 4. 
Cytotoxicity of (a) free Gem, LRSG, and LRHG and (b) free Dox and LRD after 72 h 
incubation. n = 3 identical and independent tests. Mean ± s.d.
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Fig. 5. 
Cytotoxicity of (a) free Gem, LRSG, and LRHG and (b) free Dox and LRD after short-term 
incubation. n = 5 tests of a representative batch. Mean ± s.d. Drug uptake by Huh7 after 3, 6, 
12 and 24 h incubation with (c) free Gem, LRSG, and LRHG and (d) free Dox and LRD. n = 
3 (Gem) and 4 (Dox) independent and identical tests of a representative batch. Mean ± s.d. 
*: p < 0.05, **: p < 0.01 by, ****: p < 0.0001 by two-way ANOVA test followed by Sidak’s 
multiple comparisons test.
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Fig. 6. 
Confocal microscopic images of Huh7 cells incubated with (a) free Dox or (b) 25-NBD 
cholesterol labeled *LRD for 10 min, 3 h or 10 h. + CQ: cells incubated with chloroquine 
(inhibitor of endosomal acidification) for 12 h prior to the addition of liposomal Dox. Scale 
bars: 50 μm.
Hassan et al. Page 23
Mol Pharm. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 7. 
Cytotoxicity of (a) free Gem/Dox combinations on Huh7 cells given in different sequences 
and in different molar ratios (n = 3 tests. Mean ± s.d.) and (b) free or liposomal Gem/Dox 
combinations on Huh7 cells given simultaneously in different molar ratios (n = 3 tests. mean 
± s.d.).
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Fig. 8. 
Drug concentrations in (a) plasma and (b) Huh7 tumors of animals treated with Gem + Dox 
free drug mixture or LRSG + LRD liposomal mixture at 8 h post-IV injection. n = 4 expect 
for the plasma of liposomal mixture-treated group: n = 3.
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Fig. 9. 
(a) Dosing schedule. (b) Changes of individual Huh7 tumor volume. Blue: PBS (n = 6); Red: 
Gem + Dox (n = 8); Green: LRSG + LRD (n = 7). (c) Specific growth rate of Huh7 tumor: 
ΔlogV/Δt (V: tumor volumes; t: time in days). **: p < 0.01, ***: p <0.001 by Tukey’s 
multiple comparisons test. (d) Survival curve of the animals receiving PBS, Gem + Dox, or 
LRSG + LRD. ***: p <0.001, ****: p <0.0001 by Log-rank (Mantel-Cox) test.
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Fig. 10. 
(a) Representative photographs of TUNEL-stained Huh7 tumor sections and quantitative 
analysis of TUNEL-stained sections. Top: TUNEL-stained apoptotic cells; Bottom: 
Composite images of TUNEL-stained apoptotic cells (green) and PI-stained nuclei (red); % 
apoptotic cells = number of apoptotic cells/total number of nuclei measured by a Nikon A1R 
confocal microscope (3–4 random fields per each tumor section). Scale bars: 100 μm. **: p 
< 0.01 vs. PBS by Dunn’s multiple comparisons test following Kruskal-Wallis test. For all 
images, see Supporting Fig. 8; (b) Representative H&E stained Huh7 tumor sections. Scale 
bars: 50 μm. For other organs, see Supporting Fig. 9.
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Table 2.
Physical stability of liposomes during storage
Liposomes Storage period (months) Initial size (nm) Size after 
storage at 
4 °C (nm)
Initial zeta 
potential 
(mV)
Zeta potential 
after storage at 
4 °C (mv)
% Drug Content*
1 223 ± 2 −30.2 ± 1.8 98.1 ± 2.9
LRSG 2 218 ± 13 208 ± 6 −31.8 ± 2.6 −26.6 ± 6.0 99.0 ± 1.8
3 235 ± 1 −24.0 ± 1.6 98.8 ± 2.2
1 220 ± 5 −32.1 ± 0.0 99.8 ± 3.0
LRHG 2 219 ± 19 207 ± 8 −29.6 ± 4.0 −32.2 ± 1.0 101.5 ± 2.0
3 197 ± 6 −25.5 ± 4.5 99.1 ± 1.0
1 210 ± 24 −22.0 ± 3.05 101.4 ± 1.2
LRD 2 215 ± 16 237 ± 4 −22.5 ± 3.3 −17.5 ± 0.9 98.9 ± 2.0
3 259 ± 5 −14.5 ± 3.6 97.8 ± 1.0
LRSGD 1 275 ± 1 906 ± 49 −28.7 ± 3.2 −11.9 ± 4.7 100.2 ± 1.0 (Gem)
98.7 ± 2.1 (Dox)
*% Drug content = Drug content after storage / initial drug content × 100
Data are presented as the averages ± standard deviations of 3 independently and identically prepared batches
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Table 3.
Combination indices of free drug combinations
Molar ratio (Gem:Dox) Gem → Dox (sequential) Dox → Gem (sequential) Gem + Dox (simultaneous)
5:1 0.55 0.62 0.17
1:1 0.77 0.89 0.62
1:5 0.56 0.56 0.53
Mol Pharm. Author manuscript; available in PMC 2020 January 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hassan et al. Page 31
Table 4.
Combination indices of liposomal drug combinations
Molar ratio (Gem:Dox) LRSG + LRD LRHG + LRD
5:1 0.25 0.68
1:1 0.3 0.42
1:5 0.29 0.22
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